SCYX - SCYNEXIS, Inc.
| Previous Close | 2.01 |
| Open | 2.02 |
| Bid | 1.89 x 900 |
| Ask | 1.92 x 1200 |
| Day's Range | 1.89 - 2.03 |
| 52 Week Range | 1.05 - 2.50 |
| Volume | 1,056,467 |
| Avg. Volume | 571,435 |
| Market Cap | 90.408M |
| Beta | 0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.30 |
Market Realist•3 days agoWhy Scynexis Stock Rose 16.4% Yesterday
Yesterday, Scynexis (SCYX) stock rose 16.4% on the announcement of positive data from its Phase 2b clinical trial of its drug candidate SCY-078 for the treatment of VVC (vulvovaginal candidiasis), or vaginal yeast infection. The findings were compared to treatment results for the standard of care drug Flu (fluconazole). Currently, the SCY-078 candidate is also being developed and evaluated for the treatment of a number of other serious fungal infections, including invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections. Currently, the only approved oral drug for the treatment of VVC is fluconazole, whereas there are no approved products for patients with recurrent VVC.
- PR Newswire•5 days ago
SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program Results confirm strong clinical activity of oral SCY-078 and suggest improved ...
- ACCESSWIRE•13 days ago
Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks
Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.
- PR Newswire•18 days ago
SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
JERSEY CITY, N.J., June 27, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the presentation of data at the Teratology Society 58th Annual Meeting, June 23-27, 2018 in Clearwater, Florida. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. "The treatment of fungal infections during pregnancy has long been challenging due to the well-known developmental toxicities associated with existing antifungal treatments," said David Angulo, M.D., Chief Medical Officer of SCYNEXIS.
- PR Newswire•last month
SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018
20th International Symposium on Infections in the Immunocompromised Host (ICHS) Teratology Society 58th Annual Meeting 20th Congress of the International Society for Human and Animal Mycology (ISHAM) JERSEY ...
- PR Newswire•last month
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
SCY-078 demonstrates potent in vitro activity vs. echinocandin-resistant Candida strains and synergistic activity with isavuconazole vs. Aspergillus spp. SCY-078 exhibits a profound effect on cellular ...
- PR Newswire•last month
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...
- PR Newswire•last month
SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
JERSEY CITY, N.J., June 6, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a Phase 1 study of SCY-078, assessing the risk for drug-drug interactions when administered with drugs metabolized by the CYP family of enzymes, in The Journal of Clinical Pharmacology. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. The article, "Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions," describes the Phase 1 study, in which the pharmacokinetic parameters of rosiglitazone, a thiazolidinedione agent commonly used for type 2 diabetes, were measured in the absence and presence of SCY-078 dosed to therapeutically relevant levels in healthy adult subjects.
- PR Newswire•2 months ago
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
JERSEY CITY, N.J. , May 24, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- ACCESSWIRE•2 months ago
Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares.
- PR Newswire•2 months ago
SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention
JERSEY CITY, N.J. , May 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- Market Realist•2 months ago
What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.
- Associated Press•2 months ago
Scynexis: 1Q Earnings Snapshot
The Jersey City, New Jersey-based company said it had a loss of 12 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- PR Newswire•2 months ago
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018 Phase 3 registration program in VVC planned for the fourth quarter of 2018 IV SCY-078 program continues to advance; ...
- PR Newswire•2 months ago
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
JERSEY CITY, N.J., May 1, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the oral formulation of SCY-078, SCYNEXIS's novel oral and intravenous antifungal agent, for the treatment of vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC. Additionally, SCYNEXIS today announced it has completed enrollment in the Phase 2b, dose-finding study of oral SCY-078 for the treatment of VVC (the DOVE study), with release of top-line data expected by July 2018.
- PR Newswire•3 months ago
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
Published study further demonstrates in vitro activity of SCY-078 against Aspergillus strains when used alone or in combination Clinical efficacy against Aspergillus strains to be tested in Phase 2 trial ...
- PR Newswire•3 months ago
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
- PR Newswire•3 months ago
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
JERSEY CITY, N.J. , April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening ...
- PR Newswire•4 months ago
SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
JERSEY CITY, N.J. , March 21, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening ...
- PR Newswire•4 months ago
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
Pre-clinical data demonstrates inhibitory activity of SCY-078 against C. auris Two ongoing trials - FURI and CARES - to study oral SCY-078 in patients with refractory fungal infections, including C. auris ...
- PR Newswire•4 months ago
SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
Robust enrollment continues in Phase 2b VVC trial with top-line data expected in mid-2018 IV SCY-078 program advancing, with liposomal IV formulation to be tested in a Phase 1 study in the third quarter ...
- PR Newswire•4 months ago
SCYNEXIS to Present at the 30th Annual ROTH Conference
JERSEY CITY, N.J. , March 7, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening ...
- PR Newswire•4 months ago
SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., March 6, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX) today announced the pricing of its underwritten public offering of common stock and warrants. The shares and warrants are being sold at a public offering price of $1.69 per share, the closing price of the stock on March 5, 2018. The gross offering proceeds to SCYNEXIS from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants.
- PR Newswire•4 months ago
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., March 5, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the shares of common stock and warrants in the offering will be sold by SCYNEXIS. Guggenheim Securities, LLC is serving as the sole book-running manager.
- PR Newswire•5 months ago
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
Data shows synergistic activity and improved outcomes of SCY-078 in combination with isavuconazole Phase 2 trial in invasive aspergillosis expected to initiate in the third quarter of 2018 JERSEY CITY, ...
